Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions

AbstractOsteoarthritis (OA) is the most common form of arthritis. It is characterized by progressive destruction of articular cartilage and the development of chronic pain and constitutes a considerable socioeconomic burden. Currently, pharmacological treatments mostly aim to relieve the OA symptoms associated with inflammation and pain. However, with increasing understanding of OA pathology, several potential therapeutic targets have been identified, enabling the development of disease-modifying OA drugs (DMOADs). By targeting inflammatory cytokines, matrix-degrading enzymes, the Wnt pathway, and OA-associated pain, DMOADs successfully modulate the degenerative changes in osteoarthritic cartilage. Moreover, regenerative approaches aim to counterbalance the loss of cartilage matrix by stimulating chondrogenesis in endogenous stem cells and matrix anabolism in chondrocytes. Emerging strategies include the development of senolytic drugs or RNA therapeutics to eliminate the cellular or molecular sources of factors driving OA. This review describes the current developmental status of DMOADs and the corresponding results from preclinical and clinical trials and discusses the potential of emerging therapeutic approaches to treat OA.

Download Full-text

Treatment of malignant pleural mesothelioma: current status and future directions

Monaldi Archives for Chest Disease ◽

10.4081/monaldi.2010.302 ◽

2016 ◽

Vol 73 (2) ◽

Author(s):

X. Dhalluin ◽

A. Scherpereel

Keyword(s):

Malignant Pleural Mesothelioma ◽

European Society ◽

Poor Prognosis ◽

Asbestos Exposure ◽

Therapeutic Strategies ◽

Current Status ◽

Pleural Mesothelioma ◽

European Respiratory Society ◽

Future Directions ◽

Cell Therapies

Previously considered to be rare, malignant pleural mesothelioma (MPM) is a highly aggressive tumour that has become a very important issue over recent years due to its poor prognosis and its increasing incidence mostly linked to previous asbestos exposure. An optimal treatment for MPM is not established yet; new therapies and predictive tools are still needed in the management of this cancer. Thus the aim of this review is to provide clinicians clear and up-to-dated data on the latest therapeutic strategies for MPM patients in 2010. The guidelines recently proposed by the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS) taskforce are summarized here. The authors also briefly reviewed the future directions in MPM treatment including targeted therapies, gene or cell therapies.

Download Full-text

Therapeutic Approaches Targeting Inflammation in Cardiovascular Disorders

Biology ◽

10.3390/biology7040049 ◽

2018 ◽

Vol 7 (4) ◽

pp. 49 ◽

Cited By ~ 3

Author(s):

Daniel Jones ◽

Jyoti Patel

Keyword(s):

Therapeutic Strategies ◽

Western World ◽

Therapeutic Approaches ◽

Cardiovascular Medicine ◽

Cardiovascular Research ◽

Future Directions ◽

Chronic Inflammatory Condition ◽

Inflammatory Component ◽

Made In

Cardiovascular disease is a leading cause of morbidity and mortality in the Western world and represents an enormous global health burden. Significant advances have been made in the conservative, medical and surgical management across the range of cardiovascular diseases however the inflammatory components of these diseases have traditionally been neglected. Inflammation is certainly a key component of atherosclerosis, a chronic inflammatory condition, but it is at least correlative and predictive of risk in many other aspects of cardiovascular medicine ranging from heart failure to outcomes following reperfusion strategies. Inflammation therefore represents significant potential for future risk stratification of patients as well as offering new therapeutic targets across cardiovascular medicine. This review explores the role of inflammation in several of the major aspects of cardiovascular medicine focusing on current and possible future examples of the targeting of inflammation in prognosis and therapy. It concludes that future directions of cardiovascular research and clinical practice should seek to identify cohorts of patients with a significant inflammatory component to their cardiovascular condition or reaction to cardiovascular intervention. These patients might benefit from therapeutic strategies mounted against the inflammatory components implicated in their condition.

Download Full-text